Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813190 | 0.88 | LIPG (0.53) | LPLLIPGHIF1AKLF10F11 | |
| SCHEMBL21682668 | 0.87 | HIF1A (0.50) | LPLLIPGHIF1AF11CA1 | |
| SCHEMBL16795239 | 0.87 | LIPG (0.45) | LPLLIPGHIF1AF11CA1 | |
| SCHEMBL27159868 | 0.84 | KDM4E (0.47) | LPLLIPGHIF1AF11CA1 | |
| SCHEMBL29901092 | 0.83 | LIPG (0.44) | LPLLIPGHIF1AF11CA1 | |
| SCHEMBL16831631 | 0.83 | LIPG (0.44) | LPLLIPGHIF1AF11CA1 | |
| SCHEMBL1284600 | 0.83 | F11 (0.45) | LPLLIPGF11CA1CA2 | |
| SCHEMBL30159287 | 0.82 | LIPG (0.42) | LPLLIPGF11CA1CA2 | |
| SCHEMBL16831556 | 0.82 | LIPG (0.42) | LPLLIPGF11CA1CA2 | |
| SCHEMBL15471367 | 0.82 | LIPG (0.47) | LPLLIPGHIF1AF11CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| EP-2057156-B1 | 2-METHYLMORPHOLINE PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | KUDOS PHARM LTD (GB) | 2017-02-01 | — | — | EP | disclosed |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARM LTD (GB) | 2016-03-10 | — | — | US | disclosed |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARM LTD (GB) | 2016-03-10 | — | — | US | disclosed |
| US-9102670-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-7902189-B2 | antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| WO-2008023161-A1 | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-02-28 | — | — | WO | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1603885-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004080973-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | LPL 4584/4885LIPG 4787/4885HIF1A 2066/4885 |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MTOR, RICTOR, RPTOR | LPL 4584/4885LIPG 4787/4885HIF1A 2066/4885 |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | LPL 4584/4885LIPG 4787/4885HIF1A 2066/4885 |
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | LPL 4610/4885LIPG 4801/4885HIF1A 2031/4885 |
| US-20080081809-A1 | Novel Compounds | SLC10A1, ABCB11, PKD1 | LPL 4485/4885LIPG 4152/4885HIF1A 848/4885 |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | LPL 4512/4885LIPG 2720/4885HIF1A 2719/4885 |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | LPL 4732/4885LIPG 4780/4885HIF1A 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.